Non-prescription painkillers linked to increased perinatal health risks 

Non-prescription painkillers linked to increased perinatal health risks

Embargo: 01.00 CEST Thursday 1 July 2021

1 July 2021: One of the largest studies of its kind has found women who use over-the-counter painkillers in pregnancy are around one and half times more likely to have a baby with health issues. The risk of a preterm delivery, stillbirth or neonatal death, physical defects and other problems are all higher compared with the offspring of mothers who did not take these drugs.

The increased odds of adverse neonatal outcomes associated with common analgesics such as aspirin and ibuprofen “indicates that healthcare guidance for pregnant women” regarding their use “should be reassessed” says first investigator Aikaterini Zafeiri from the University of Aberdeen, Scotland. Zafeiri will present the findings which span 30 years at the 37th virtual Annual Meeting of ESHRE.

A high percentage (between 30% and 80%) of women globally use non-prescription painkillers in pregnancy to relieve pain. This includes for common pregnancy symptoms, flu, fever, inflammatory or rheumatological conditions. However, current evidence regarding safety of use during gestation varies widely, with some drugs considered safe and others not.

For this analysis, data was used from the Aberdeen Maternity and Neonatal Databank spanning 1985 to 2015. A total of 151,141 singleton pregnancies were analysed using medical notes for consumption of five painkillers – paracetamol, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac, naproxen and ibuprofen - either as single compounds or in combinations.

Overall, results showed that nearly three in ten (29%) women were found to have taken over-the-counter analgesics during pregnancy, a figure which more than doubled to 60% during the last seven years of the 30-year study period. This suggests use is growing rapidly. When asked specifically at their first antenatal clinic visit, as opposed to later in pregnancy or after labour, more than four in five (84%) of women using painkillers reported use during the first 12 weeks after conception.

The findings show an association between increased health risks for pregnancies, where mothers were exposed to at least one of the five analgesics. These follow, ranked in order of significance according to adjusted odds ratio (AOR): neural tube defects (1.64% AOR); admission to a neonatal unit (1.57% AOR); neonatal death (1.56% AOR); premature delivery before 37 weeks (1.50% AOR); baby’s condition at birth based on APGAR score of less than 7 at 5 minutes (1.48% AOR); stillbirth (1.33% AOR); birthweight under 2.5kg (1.28% AOR); hypospadias, a birth defect affecting the penis (1.27% AOR); baby’s condition at birth based on APGAR score of less than 7 at 1 minute (1.18% AOR); and birth weight over 4kg (1.09% AOR).

Associations of paracetamol use alone with high birth weight, neural tube defects and hypospadias were not significant. Diclofenac consumption was associated with significantly decreased odds of stillbirth, a protective effect which the authors say may be attributed to its stronger anti-inflammatory effects than the other NSAIDs.

In light of the study findings, Zafeiri says the ease of access to non-prescription painkillers, in combination with availability of correct or mis-information through the internet, raises safety concerns. She adds: “This is especially when mis-informed or partially-informed self-medication decisions are taken during pregnancy.”

Poster 732
Maternal over-the-counter analgesics use during pregnancy and adverse perinatal outcomes: cohort study of 151,141 singleton pregnancies

Notes

  1. Healthcare regulators have deemed some analgesic compounds safe to use during pregnancy such as paracetamol.
  2. However, contraindications exist for non-steroidal anti-inflammatory drugs (NSAIDs)beyond week 30 of pregnancy.
  3. Results from current studies into the safety of painkillers during pregnancy in humans are largely conflicting. Many have been limited by small cohorts, short study time or failure to adjust for important confounding factors such as maternal deprivation or other medical conditions during pregnancy.
    This has hampered the development of evidence-based prenatal guidance for mothers-to-be.

* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.

 

For further information on the details of this press release, contact:

Laura Rossignoli at ESHRE

Mobile: +32 (0)499 92 32 49

Email: [email protected]